Clinical therapeutics
-
Clinical therapeutics · May 2010
ReviewTreatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Imatinib has been found to substantially improve outcomes in patients with chronic myeloid leukemia (CML) compared with previously available therapies. However, its use is complicated by development of resistance or drug intolerance, prompting dose escalation or a trial of dasatinib or nilotinib, the second-generation tyrosine kinase inhibitors (TKIs). ⋯ Dasatinib and nilotinib were effective and generally well tolerated as second-line treatments for CML patients with a suboptimal response to standard doses of imatinib or imatinib intolerance.